RDR Holdings LLC

RDR Holdings LLC was paid $3.34M by Medicaid between Sep 2021 and Nov 2024, across 18 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 90% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#126 of 561

Median peer was paid$222K

This provider vs. median15×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2021	71,513	$1.52M
2022	37,465	$1.77M
2023	40	$0.00
2024incomplete	5,751	$59K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	90%	64,608	32,106	$3.00M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	3.9%	38,306	18,195	$132K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	2.5%	5,033	2,707	$83K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	2.0%	1,031	727	$68K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	824	585	$32K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	344	177	$11K
87529		<1%	394	382	$4K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	536	474	$3K
87511		<1%	374	365	$2K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	394	382	$2K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	379	367	$2K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	379	367	$2K

6 more codes

87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	535	$568.08
87640		<1%	536	$568.06
87500		<1%	498	$565.27
87641		<1%	495	$565.16
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	63	$204.73
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	0%	40	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialRAINONE, BRANDON (OWNER)